Assessing Catecholamine Treatment Initiation Options: Norepinephrine vs Dopamine for Cardiogenic Shock
NCT07562932
Summary
The goal of this multicenter, open-label, randomized clinical trial is to learn whether norepinephrine or dopamine is more effective and safer as the first-line vasoactive drug for treating cardiogenic shock in adults. Cardiogenic shock is a life-threatening condition in which the heart cannot pump enough blood to supply the body. The main questions this study aims to answer are: Does norepinephrine reduce the risk of death or worsening cardiogenic shock compared with dopamine? Does norepinephrine lead to fewer complications such as arrhythmias, the need for mechanical circulatory support, or cardiac arrest? Researchers will compare norepinephrine and dopamine to see which drug better stabilizes blood pressure, improves tissue perfusion, and prevents progression of shock during the early phase of treatment. Participants will: Be randomly assigned to receive either norepinephrine or dopamine as the first vasoactive drug Receive treatment and monitoring based on current clinical guidelines for cardiogenic shock Undergo regular assessments of blood pressure, laboratory values, heart rhythm, and organ function during hospitalization Be followed for outcomes at 1 month, 6 months, and 1 year after enrollment This study aims to provide evidence that will help determine which initial vasoactive drug offers better outcomes for patients with cardiogenic shock and guide future treatment recommendations.
Eligibility
Inclusion Criteria: 1\&2
1. Age ≥ 19
2. Cardiogenic shock (a) in the stage of Society for cardiovascular angiography and intervention (SCAI) C or D
* Cardiogenic shock (a) was defined as follows, and should fulfill both 1) and 2)
1. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And
2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography
a Cardiogenic shock was defined as follows, and should fulfill both 1) and 2)
<!-- -->
1. systolic blood pressure \<90 mm Hg for ≥30 min or need of inotropes or vasopressors to maintain systolic blood pressure \>90 mm Hg And
2. Impaired cardiac function confirmed by cardiac catheterization or echocardiography
* Cardiac index (CI) \< 2.2 L/min/m², measured by pulmonary artery catheter
* Left ventricular ejection fraction LVEF \< 45% on echocardiography;
* Right ventricular dysfunction, defined by one or more of: TAPSE \< 17 mm; S' \< 9.5 cm/sec; FAC \< 35%11; or visual estimation of RV wall motion abnormality.
Or Structural cardiac abnormality capable of causing cardiogenic shock, even if LV/RV systolic indices do not meet the thresholds above (examples, infarct ventricular septal rupture or severe valvular regurgitation)
Patients will be further classified based on the SCAI shock classification system12 as follows:
* SCAI B: no signs of hypoperfusion
* SCAI C: any signs of hypoperfusion, cardiogenic shock will be classified as SCAI C, and these include mental status change, cool and clammy skin, mottled skin appearance, decreased urine output (30ml/hour) or lactate over 2.0mmol/L
* SCAI D: shock progression despite use of the index vasoactive agent at ≥75% of the predefined maximal dose
* SCAI E: Impending arrest or overt circulatory collapse
Exclusion Criteria: any of these,
1. Administration of vasoactive drug more than 6 hours before enrollment
2. Receiving norepinephrine or dopamine at doses exceeding the protocol defined maximal dose at the time of enrollment.
3. Receiving any vasoactive agent other than norepinephrine or dopamine
4. Patients receiving a continuous infusion of both norepinephrine and dopamine
5. Patients already on temporary mechanical circulatory supportb before enrollment
6. Cardiogenic shock in the stage of SCAI E
7. Glasgow Coma Scale lower than 8 or other evidence of irreversible brain injury
8. Shock etiologies other than cardiogenic which include postcardiotomy shock or mixed shock
9. Pregnancy or lactationConditions2
Interventions2
Related trials
- Effect of Ephedrine, Phenylepinephrine, and Norepinephrine on Myometrial Contractility in Pregnant People With Type II and Gestational Diabetes During Cesarean Section: An In-vitro Study — Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Effects of Ephedrine, Phenylephrine, Norepinephrine and Vasopressin on Contractility of Human Myometrium and Umbilical Vessels: An In-vitro Study — Samuel Lunenfeld Research Institute, Mount Sinai Hospital
- Vasopressor Agents in Pulmonary Hypertension Crisis — China National Center for Cardiovascular Diseases
- The Choice of Vasopressor to Prevent Postoperative Acute Kidney Injury After Major Non-Cardiac Surgery — University of California, San Francisco
- Vasoactive Drugs in Intensive Care Unit — University of Chicago
Browse More Trials
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.
NCT07562932